2. Search Result
Search Result
Results for "

hematologic

" in MedChemExpress (MCE) Product Catalog:

90

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

3

Peptides

9

Inhibitory Antibodies

5

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131341
    Syk-IN-4

    		Syk Inflammation/Immunology Cancer
    Syk-IN-4 is a potent, selective and orally bioavailable SYK inhibitor with an IC50 of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers .
    Syk-IN-4
  • HY-129179B
    (Rac)-Lisaftoclax

    (Rac)-APG-2575

    		 Bcl-2 Family Cancer
    (Rac)-Lisaftoclax ((Rac)-APG-2575) is a Bcl-2 inhibitor that can be uesd for hematologic malignancy research (CN112898295A) .
    (Rac)-Lisaftoclax
  • HY-160487
    KME-2780

    		IRAK Cancer
    KME-2780 is a potent and selective dual IRAK1 and IRAK4 inhibitor and can be used for research of dysregulation of innate immune signaling and hematologic malignancies .
    KME-2780
  • HY-143584
    AZ5576

    		CDK Cancer
    AZ5576 is a potent and highly selective CDK9 inhibitor (IC50: <5 nM). AZ5576 can be used for hematological Malignancy research .
    AZ5576
  • HY-145813
    MU1656

    		Histone Methyltransferase Cancer
    MU1656 is a potent and selective inhibitor of histone methyltransferase DOT1L, with an IC50 of 2 nM. MU1656 can be used for the research of hematological malignancies .
    MU1656
  • HY-D1472
    Azure A eosinate

    		Fluorescent Dye Others
    Azure A eosinate is a dye for hematological and histological applications. Azure A eosinate can be used as new photosensitizer prototypes to determine growth inhibition of Candida albicans .
    Azure A eosinate
  • HY-15901A
    LGB321 monohydrochloride

    		Pim mTOR Cancer
    LGB321 monohydrochloride is a potent, selective, orally active and ATP competitive inhibitor of all three PIM kinases. LGB321 monohydrochloride inhibits proliferation, mTOR-C1 signaling and phosphorylation of BAD in a number of cell lines derived from diverse hematologic malignancies. LGB321 monohydrochloride can be used for the research of hematologic malignancies .
    LGB321 monohydrochloride
  • HY-P990077
    Pidilizumab

    CT-011; MDV9300

    		 PD-1/PD-L1 Cancer
    Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research .
    Pidilizumab
  • HY-156794
    Enzomenib

    		Others Cancer
    Enzomenib is an inhibitor of the menin protein encoded by the multiple endocrine neoplasia (MEN) gene. Enzomenib can block the binding of the menin protein to mixed lineage leukemia (MLL) fusion proteins and can be used in the study of hematological malignancies .
    Enzomenib
  • HY-P99952
    Ripertamab

    SCT400

    		 CD20 Cancer
    Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .
    Ripertamab
  • HY-139453A
    LP-284

    		DNA Alkylator/Crosslinker Cancer
    LP-284 is a potent DNA alkylating agent that kills solid tumours. LP-284 can be used in the studies of hematologic cancers with compromised DNA repair, such as mantle cell lymphoma (MCL) .
    LP-284
  • HY-125378
    SBP-0636457

    SBI-0636457; SB1-0636457

    		 IAP Cancer
    SBP-0636457 (SB1-0636457) is a SMAC mimetic, and as an IAP antagonist. SBP-0636457 binds to the BIR-domains of the IAP proteins, with a Ki of 0.27 μM. SBP-0636457 can be used for the research of solid tumors and hematologic cancers .
    SBP-0636457
  • HY-124676A
    DB2115 tertahydrochloride
    1 Publications Verification

    		 Apoptosis Cancer
    DB2115 (tertahydrochloride) is a potent inhibitor of myeloid master regulator PU.1. DB2115 (tertahydrochloride) has the potential for researching cancers, including hematologic cancers such as leukemia, as well as other conditions associated with PU. 1 dysfunction (extracted from patent WO2017223260A1, compound DB2115) .
    DB2115 tertahydrochloride
  • HY-P99475
    Betifisolimab

    MSB-2311

    		 PD-1/PD-L1 Cancer
    Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .
    Betifisolimab
  • HY-167880
    BMY-25551

    		Others Cancer
    BMY-25551 is a Mitomycin A (HY-130332) analogue that is 8 to 20 times more potent than Mitomycin C (HY-13316) in cytotoxicity to murine and human tumor cell lines. BMY-25551 can be utilized in cancer and hematologic depression research .
    BMY-25551
  • HY-136506
    NUC-7738

    		Others Cancer
    NUC-7738, an aryloxy phosphoramidate of 3′-Deoxyadenosine, is a 5′-aryloxy phosphoramidate prodrug of 3′-Deoxyadenosine (3′-dA). NUC-7738 has potent cytotoxic activity against a panel of hematological cancer cell lines. NUC-7738 can be used in research of cancer .
    NUC-7738
  • HY-128436
    KT-531

    		HDAC Cancer
    KT-531 is a potent and selective inhibitor of HDAC6 with an IC50 of 8.5 nM. KT-531 exhibits strong inhibition against SUP-T11 cells with an IC50 of 0.42 μM. KT-531 can be used in study hematological cancers .
    KT-531
  • HY-P990033
    Anzurstobart

    CC-95251; BMS-986351

    		 CD47 Cancer
    Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
    Anzurstobart
  • HY-124593
    PTC299
    2 Publications Verification

    		 VEGFR Dihydroorotate Dehydrogenase DNA/RNA Synthesis Cancer
    PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies .
    PTC299
  • HY-150586
    PTG-0861

    		HDAC Apoptosis Cancer
    PTG-0861 is a selective histone deacetylase 6 (HDAC6) inhibitor with the IC50 value of 5.92 nM. PTG-0861 induces apoptosis and can be used in the study of acute myeloid leukemia, multiple myeloma and other hematological cancers .
    PTG-0861
  • HY-125378A
    (7R)-SBP-0636457

    (7R)-SBI-0636457; (7R)-SB1-0636457

    		 Others Cancer
    (7R)-SBP-0636457 is the isomer of SBP-0636457 (HY-125378), and can be used as an experimental control. SBP-0636457 (SB1-0636457) is a SMAC mimetic, and as an IAP antagonist. SBP-0636457 binds to the BIR-domains of the IAP proteins, with a Ki of 0.27 μM. SBP-0636457 can be used for the research of solid tumors and hematologic cancers .
    (7R)-SBP-0636457
  • HY-101870B
    Uzansertib phosphate

    INCB053914 phosphate

    		 Pim Cancer
    Uzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC50s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib phosphate has broad anti-proliferative activity against a variety of hematologic tumor cell lines .
    Uzansertib phosphate
  • HY-101870
    Uzansertib

    INCB053914

    		 Pim Cancer
    Uzansertib (INCB053914) is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC50s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib has broad anti-proliferative activity against a variety of hematologic tumor cell lines .
    Uzansertib
  • HY-114414
    HDACs/mTOR Inhibitor 1
    1 Publications Verification

    		 HDAC mTOR Apoptosis Cancer
    HDACs/mTOR Inhibitor 1 is a dual HDACs and mTOR inhibitor, with IC50s of 0.19 nM, 1.8 nM, 1.2 nM for HDAC1, HDAC6, mTOR, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induces tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1 can be used in the research of hematologic malignancies .
    HDACs/mTOR Inhibitor 1
  • HY-P99172
    CC-90002

    		CD47 Interleukin Related Cancer
    CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
    CC-90002
  • HY-136241
    OT-82

    		NAMPT Caspase Cancer
    OT-82 is a potent, selective and orally active inhibitor of NAMPT. OT-82 is selectively toxic to cells of hematopoietic origin and induces cell death in a NAD + dependent manner. OT-82 is a promising antineoplastic agent for the study of hematological malignancies .
    OT-82
  • HY-161694
    DNMT1-IN-3

    		DNA Methyltransferase Cancer
    DNMT1-IN-3 (compound 7t-S) is an effective DNA methyltransferase 1 (DNMT1) inhibitor with an IC50 value of 0.777 μM and a KD value of 0.183 μM. DNMT1-IN-3 can bind to the methyl donor S-adenosyl-l-methionine (SAM) site in DNMT1. DNMT1-IN-3 can inhibit cell proliferation in K562 cells by inducing cells apoptosis and arresting cell cycle at G0 / G1 phase, which has the potential to be used for the research of hematologic tumor .
    DNMT1-IN-3
  • HY-144039
    DNA-PK-IN-6

    		DNA-PK Cancer
    DNA-PK-IN-6 is a potent inhibitor of DNA-PK. DNA-PK-IN-6 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-6 enhances the sensitivity of tumor tissues to radiotherapy, overcomes the problem of agent resistance, and enhances the inhibitory effect on a variety of solid tumors and hematological tumors (extracted from patent WO2021197159A1, compound 6) .
    DNA-PK-IN-6
  • HY-144038
    DNA-PK-IN-5

    		DNA-PK Cancer
    DNA-PK-IN-5 is a potent inhibitor of DNA-PK. DNA-PK-IN-5 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-5 enhances the sensitivity of tumor tissues to radiotherapy, overcomes the problem of agent resistance, and enhances the inhibitory effect on a variety of solid tumors and hematological tumors (extracted from patent WO2021204111A1, compound 2) .
    DNA-PK-IN-5
  • HY-118084
    LS-104

    Tyrene CR-4

    		 JAK Bcr-Abl FLT3 Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    LS-104 (Tyrene CR-4) is a non-ATP-competitive kinase inhibitor against JAK2, Bcr-Abl and FLT3. LS-104 potently induces apoptosis in JAK2V617F-positive cells and inhibits JAK2 autophosphorylation and downstream signal transduction. LS-104 also inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells. LS-104 is a hydroxystyryl-acrylonitrile compound, which is promising for research of myeloproliferative disorders and refractory/relapsed hematologic malignancies .
    LS-104
  • HY-169075
    CDK/HDAC-IN-4

    		HDAC CDK Apoptosis Cancer
    CDK/HDAC-IN-4 is a high selective dual cyclin-dependent kinase (CDK)/histone deacetylase (HDAC) inhibitor with IC50 values of 88.4 and 168.9 nM, respectively. CDK/HDAC-IN-4 exhibits antiproliferative capacities against hematological and solid tumor cells. CDK/HDAC-IN-4 also induces MV-4-11 cell Apoptosis and S cell cycle arrests. CDK/HDAC-IN-4 possesses a significant antitumor potency in the MV-4-11 xenograft model .
    CDK/HDAC-IN-4
  • HY-149283
    JAK/HDAC-IN-2

    		JAK HDAC Apoptosis Cancer
    JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine JAK/HDAC dual-target inhibitor. JAK/HDAC-IN-2 potently inhibits HDAC3/6 and JAK1/2 at nanomolar levels. JAK/HDAC-IN-2 has proapoptotic activity and inhibits histone deacetylation and STAT3 phosphorylation. JAK/HDAC-IN-2 presents remarkable antiproliferative activity in both hematological malignancies and solid cancers .
    JAK/HDAC-IN-2
  • HY-112088
    AZD4573
    5+ Cited Publications

    		 CDK Cancer
    AZD4573 is a potent and highly selective CDK9 inhibitor (IC50 of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies .
    AZD4573
  • HY-13468
    KW-2478
    3 Publications Verification

    		 HSP Cancer
    KW-2478 is an inhibitor of Hsp90α, with an IC50 of 3.8 nM, and has antitumor activity against various human hematological tumor cells.
    KW-2478
  • HY-156602
    Bocodepsin

    OKI-179

    		 HDAC Cancer
    Bocodepsin (OKI-179) is an orally active and selective HDAC inhibitor, with antitumor activity. Bocodepsin can be used for suppression on solid tumor and hematologic malignancies .
    Bocodepsin
  • HY-156602A
    Bocodepsin hydrochloride

    OKI-179 hydrochloride

    		 HDAC Cancer
    Bocodepsin hydrochloride (OKI-179) is an orally active and selective HDAC inhibitor, with antitumor activity. Bocodepsin hydrochloride can be used for suppression on solid tumor and hematologic malignancies .
    Bocodepsin hydrochloride
  • HY-157215
    HDAC-IN-66

    		HDAC Cancer
    HDAC-IN-66 (compound 2F) is a selective HDAC inhibitor and Pomalidomide (HY-10984) derivative that potently inhibits hematological tumor cells .
    HDAC-IN-66
  • HY-13892
    Dovitinib dilactic acid

    CHIR-258 dilactic acid; TKI258 dilactic acid

    		 VEGFR Cancer
    Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis .
    Dovitinib dilactic acid
  • HY-144993
    PI3Kδ/γ-IN-1

    		PI3K Cancer
    PI3Kδ/γ-IN-1 is a potent, selective PI3K-δ/γ inhibitor for research of hematological malignancies.
    PI3Kδ/γ-IN-1
  • HY-109174
    Fosciclopirox

    CPX-POM

    		 γ-secretase Metabolic Disease Cancer
    Fosciclopirox suppresses growth of urothelial cancer by targeting the γ-secretase complex. Fosciclopirox selectively delivers the active metabolite, Ciclopirox (CPX), to the entire urinary tract . Ciclopirox has anticancer activity in a number of solid and hematologic malignancies.
    Fosciclopirox
  • HY-155513
    Syk-IN-8

    		Syk Cancer
    Syk-IN-8 (compound 19q) is a Syk inhibitor, with antiproliferative activity against multiple hematological tumour cells. Syk-IN-8 inhibits PLCγ2 phosphorylation, can be used for research in blood cancers .
    Syk-IN-8
  • HY-108418
    PI3Kδ-IN-15
    1 Publications Verification

    		 PI3K Cancer
    PI3Kδ-IN-15 (compound 6b) is a selective PI3Kδ inhibitor with an IC50 of 0.5 nM for p110δ. PI3Kδ-IN-15 inhibits PI3Kδ with >30-fold higher potency than PI3Kγ, PI3Kβ, and PI3Kα .
    PI3Kδ-IN-15
  • HY-146358
    Anticancer agent 49

    		Microtubule/Tubulin Cancer
    Anticancer agent 49 (compound 69) is a broad spectrum anticancer agent. Anticancer agent 49 inhibits tubulin polymerization. Anticancer agent 49 shows antiproliferative activity. Anticancer agent 49 has the potential for the research of solid and hematological tumors .
    Anticancer agent 49
  • HY-149672
    ABBV-467

    		Bcl-2 Family Apoptosis Cancer
    ABBV-467 is a selective MCL-1 inhibitor (Ki: <0.01 nM). ABBV-467 induces apoptosis. ABBV-467 induces cancer cell death and inhibits tumor growth in models of hematological malignancies, such as multiple myeloma .
    ABBV-467
  • HY-W011180
    Vitamin A Propionate

    		Others Others
    Vitamin A Propionate is an ester compound of vitamin A. In nutritional studies of foals, different doses have different effects on growth, serum biochemistry and hematological indicators. Too high or too low doses will produce adverse effects and are related to the vitamin A concentration in plasma, liver and kidneys.
    Vitamin A Propionate
  • HY-128587
    Mevociclib
    4 Publications Verification

    SY-1365

    		 CDK Cancer
    Mevociclib (SY-1365) is a potent and first-in-class selective CDK7 inhibitor, with a Ki of 17.4 nM. Mevociclib exhibits anti-proliferative and apoptotic effects in solid tumor cell lines. Mevociclib possesses anti-tumor activity in hematological and multiple aggressive solid tumors .
    Mevociclib
  • HY-109174A
    Fosciclopirox disodium

    CPX-POM disodium

    		 γ-secretase Metabolic Disease Cancer
    Fosciclopirox disodium suppresses growth of urothelial cancer by targeting the γ-secretase complex. Fosciclopirox disodium selectively delivers the active metabolite, Ciclopirox (HY-B0450), to the entire urinary tract. Ciclopirox has anticancer activity in a number of solid and hematologic malignancies .
    Fosciclopirox disodium
  • HY-A0236
    Aprindine

    		Others Cardiovascular Disease
    Aprindine is an arrhythmia inhibitor that stabilizes the cell membranes of heart muscle cells, thereby preventing abnormal electrical impulses from causing irregular heartbeats. In hematological toxicity studies, aprindine showed potential inhibitory effects on the replicative capacity of mouse and human blood cells at certain concentrations .
    Aprindine
  • HY-P99776
    Plamotamab

    XmAb-13676

    		 CD20 CD3 Cancer
    Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
    Plamotamab
  • HY-10984A
    (S)-Pomalidomide

    (S)-CC-4047

    		 Others Cancer
    (S)-Pomalidomide ((S)-CC-4047) is an angiogenesis-inhibiting drug with growth-inhibitory activity against B-cell tumors. (S)-Pomalidomide can induce complete tumor regression in BurKitt lymphoma cells. (S)-Pomalidomide serves as an immunomodulator with potential applications in inhibiting hematological malignancies .
    (S)-Pomalidomide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: